Annual report pursuant to Section 13 and 15(d)

Related Party Agreements (Narrative) (Details)

v3.24.0.1
Related Party Agreements (Narrative) (Details)
 12 Months Ended
Jan. 01, 2024
shares
Jan. 01, 2023
shares
Jan. 01, 2017
USD ($)
shares
Jul. 26, 2016
USD ($)
shares
Jul. 22, 2016
Mar. 13, 2015
Dec. 31, 2023
USD ($)
item
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2016
shares
Related Party Transaction [Line Items]                  
Shares issued for services (in shares) | shares   187,134              
Common stock, shares issuable | shares             419,089 187,134  
General and administrative             $ 9,686,000 $ 12,210,000  
Research and development             40,513,000 62,475,000  
Preferred stock voting rights multiplier       1.1          
Proceeds from debt issuance             0 30,000,000  
Research and development for licenses acquired             $ 527,000 $ 1,474,000  
Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares             36,230 23,888  
At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares             $ 163,000 $ 6,600,000  
Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Common stock, shares outstanding | shares             8,374,869 7,100,111  
Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Shares issuable on conversion, per share converted | shares       1          
Class A common shares                  
Related Party Transaction [Line Items]                  
Common stock, shares outstanding | shares             845,385 845,385  
Fortress Biotech, Inc [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from related party debt       $ 2,000,000.0          
Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses             50.00%    
Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses             50.00%    
Shares issued for services (in shares) | shares 353,086           66,003 13,131  
Common stock, shares issuable | shares             1,297    
Proceeds from issuance of common shares             $ 200,000 $ 6,600,000  
Percentage of fully diluted equity 2.50% 2.50%         2.50% 2.50%  
Expenses from related party transaction             $ 1,000,000.0 $ 500,000  
Founders agreement term       15 years          
Agreement renewal term       1 year          
Paid in kind dividend, period prior to payment date for measuring ownership       1 day          
Equity fee, period for payment after financing             5 days    
Equity fee payable in shares (as a percent)             (2.50%)    
Cash fee (as a percent)             (4.50%)    
Cash fee, period for payment             90 days    
Change in control fee, multiplier | item             5    
Change in control fee, measurement period             12 months    
Change in control fee, specified rate component             4.50%    
MSA agreement term           5 years      
MSA agreement renewal term           5 years      
Annual consulting fee             $ 500,000    
Consulting fee when net assets exceed threshold             1,000,000.0    
Net assets threshold             100,000,000    
Stock dividend (as a percent)       2.50%          
Research and development for licenses acquired             500,000 1,100,000  
Fortress Biotech, Inc [Member] | At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares             4,400,000    
Fortress Biotech, Inc [Member] | Class B Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Common stock, shares issuable | shares                 7,000,000
Fortress Biotech, Inc [Member] | Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued in conversion | shares       7,000,000.0          
Fortress Biotech, Inc [Member] | Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Percentage of fully diluted equity         2.50%        
Number of shares issued in conversion | shares       250,000          
License Agreements [Member]                  
Related Party Transaction [Line Items]                  
Research and development for licenses acquired             527,000 1,474,000  
License Agreements [Member] | Fortress Biotech, Inc [Member]                  
Related Party Transaction [Line Items]                  
Research and development             500,000 1,100,000  
Sponsored Research and Clinical Trial Agreements [Member]                  
Related Party Transaction [Line Items]                  
Research and development             4,162,000 6,989,000  
Parent Company | Founders Agreement | Fortress Biotech, Inc [Member]                  
Related Party Transaction [Line Items]                  
Percentage of fully diluted equity 2.50% 2.50%              
General and administrative             100,000 200,000  
Research and development for licenses acquired             500,000 1,100,000  
Director [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction             100,000 100,000  
Annual consulting fee             50,000    
Value of shares granted as compensation             $ 50,000 $ 50,000  
Director [Member] | Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares             7,246 4,777  
Director [Member] | Maximum                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation             $ 50,000    
Number of shares granted as compensation | shares             10,000    
Board of Directors Chairman [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction             $ 110,000 $ 110,000  
Annual consulting fee     $ 60,000            
Value of shares granted as compensation             $ 50,000 $ 50,000  
Board of Directors Chairman [Member] | Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares             7,246 4,777  
Board of Directors Chairman [Member] | Maximum                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation     $ 50,000            
Number of shares granted as compensation | shares     10,000